Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 5/20 | 0.54 |
| ▸ | DRD2 | P14416 | 4/20 | 0.52 |
| ▸ | DRD3 | P35462 | 4/20 | 0.52 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.48 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23500656 | 0.92 | HDAC1 (0.48) | HDAC1DRD2DRD3JAK1HCAR3 | |
| SCHEMBL383016 | 0.84 | DRD2 (0.55) | DRD2DRD3HCAR3NPC1RAB9A | |
| SCHEMBL17832692 | 0.83 | P2RY12 (0.49) | HDAC1DRD2DRD3NPC1RAB9A | |
| SCHEMBL22199346 | 0.82 | MAPK1 (0.56) | HDAC1DRD2DRD3JAK1AKT1 | |
| SCHEMBL185452 | 0.81 | HCAR3 (0.64) | HDAC1HCAR3HDAC3HDAC2HDAC6 | |
| SCHEMBL6501602 | 0.81 | KDM4E (0.56) | DRD2DRD3KMT2A | |
| SCHEMBL17832701 | 0.80 | HDAC1 (0.55) | HDAC1JAK1HCAR3HDAC3HDAC2 | |
| SCHEMBL16047037 | 0.79 | HCAR3 (0.62) | HDAC1HCAR3HDAC3HDAC2HDAC6 | |
| SCHEMBL17832734 | 0.79 | LTA4H (0.56) | HDAC1HDAC6NPC1RAB9AKMT2A | |
| SCHEMBL16048668 | 0.77 | HDAC3 (0.73) | HDAC1HCAR3HDAC3HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3725787-B1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230348389-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11702389-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-10968180-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2021-04-06 | — | — | US | disclosed |
| EP-3292113-B1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS LLC (US) | 2020-07-08 | — | — | EP | disclosed |
| US-10358421-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2019-07-23 | — | — | US | disclosed |
| US-10239837-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180022702-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | ACETYLON PHARMACEUTICALS, INC. | 2018-01-25 | — | — | US | disclosed |
| US-9790180-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160168093-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168093-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | HDAC1, HDAC2, HDAC10 | HDAC1 1/4885DRD2 1965/4885DRD3 2720/4885 |
| US-11702389-B2 | Piperidine derivatives as HDAC1/2 inhibitors | HDAC1, HDAC2, HDAC10 | HDAC1 1/4885DRD2 1965/4885DRD3 2720/4885 |
| US-20230348389-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | HDAC1, HDAC2, HDAC10 | HDAC1 1/4885DRD2 1965/4885DRD3 2720/4885 |
| US-10968180-B2 | Piperidine derivatives as HDAC1/2 inhibitors | HDAC1, HDAC2, HDAC10 | HDAC1 1/4885DRD2 1965/4885DRD3 2720/4885 |
| US-10239837-B2 | Piperidine derivatives as HDAC1/2 inhibitors | HDAC1, HDAC2, HDAC10 | HDAC1 1/4885DRD2 1965/4885DRD3 2720/4885 |
| US-10358421-B2 | Piperidine derivatives as HDAC1/2 inhibitors | HDAC1, HDAC2, HDAC10 | HDAC1 1/4885DRD2 1965/4885DRD3 2720/4885 |
| US-20180022702-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | HDAC1, HDAC2, HDAC10 | HDAC1 1/4885DRD2 1965/4885DRD3 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.